While this is not surprising in light of the Warburg effect [192], the realization that mitochondrial metabolism may serve as a treatment target is gaining traction, and there have been numerous reports describing the involvement of COX assembly factors, including COX16 [193] and COA4 [194], in breast cancer and COA1 [195] in bone cancer. This evidence concerns the gene COX5A and breast cancer.